Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nasal polyps
Pharma
Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek has bought out Optinose and its chronic rhinosinusitis nasal spray Xhance for $330M.
Kevin Dunleavy
Mar 20, 2025 11:23am
Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk
Mar 3, 2025 11:52am
AstraZeneca's Fasenra hit with FDA rejection
Mar 14, 2022 10:20am
GSK's Nucala scored a class-first IL-5 win in nasal polyps
Jul 29, 2021 4:42pm
GlaxoSmithKline's Nucala snags FDA nod for blood cell syndrome
Sep 28, 2020 10:00am
AZ's Fasenra chases GSK, Sanofi-Regeneron in nasal polyps
Sep 10, 2020 10:59am
